

1. Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, Angelova M, Gini B, Tamaki W, Allegakoen P, Wu W, Humpton TJ, Hill W, Tomaschko M, Lu WT, Haderk F, Al Bakir M, Nagano A, Gimeno-Valiente F, de Carné Trécesson S, Vendramin R, Barbè V, Mugabo M, Weeden CE, Rowan A, McCoach CE, Almeida B, Green M, Gomez C, **Nanjo S**, Barbosa D, Moore C, Przewrocka J, Black JRM, Grönroos E, Suarez-Bonnet A, Priestnall SL, Zverev C, Lighterness S, Cormack J, Olivas V, Cech L, Andrews T, Rule B, Jiao Y, Zhang X, Ashford P, Durfee C, Venkatesan S, Temiz NA, Tan L, Larson LK, Argyris PP, Brown WL, Yu EA, Rotow JK, Guha U, Roper N, Yu J, Vogel RI, Thomas NJ, Marra A, Selenica P, Yu H, Bakhoun SF, Chew SK, Reis-Filho JS, Jamal-Hanjani M, Vousden KH, McGranahan N, Van Allen EM, Kanu N, Harris RS, Downward J, Bivona TG, Swanton C. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. **Nat Genet.** 2024 Jan;56(1):60-73. doi: 10.1038/s41588-023-01592-8. Epub 2023 Dec 4.
2. Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M, **Tambo Y**, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. **Mol Oncol.** 2024 Feb;18(2):305-316. doi: 10.1002/1878-0261.13542. Epub 2023 Oct 28.
3. Hasegawa Y, **Okazaki A**, **Iwasaki K**. Ultrasound-assisted insertion of a small-diameter thoracic catheter for acute dorsal empyema. **Clin Case Rep.** 2024 Mar 3;12(3): e8576. doi: 10.1002/ccr3.8576. eCollection 2024 Mar.
4. Ishibashi K, Ichinose T, Kadokawa R, Mizutani R, Iwabuchi S, Togi S, Ura H, Tange S, Shinjo K, Nakayama J, **Nanjo S**, Niida Y, Kondo Y, Hashimoto S, Sahai E, **Yano S**, Nakada M, Hirata E. Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. **Dev Cell.** 2024 Mar 11;59(5):579-594. e6. doi: 10.1016/j.devcel.2024.01.010. Epub 2024 Feb 2.
5. Fujita H, **Arai S**, Arakawa H, Hamamoto K, Kato T, Arai T, Nitta N, Hotta K, Hosokawa N, Ohbayashi T, Takahashi C, Inokuma Y, Tamai I, **Yano S**, Kunishima M, Watanabe Y. Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers. **Bioorg Med Chem.** 2024 Mar 15;102:117674. doi: 10.1016/j.bmc.2024.117674. Epub 2024 Mar 2.
6. Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto

- K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer. **Clin Cancer Res.** 2025 Mar 17;31(6):1127-1141. doi: 10.1158/1078-0432.CCR-24-1762.
7. Koba H, Yoneda T, Morita H, Kimura H, Murase Y, Terada N, Tambo Y, Horie M, Kasahara K, Matsumoto I, Yano S. Genomic evolutionary analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series. **Thorac Cancer.** 2024 Mar;15(8):661-666. doi: 10.1111/1759-7714.15241. Epub 2024 Feb 7.
 8. Yamamura K, Hara J, Watanabe S, Kobayashi T, Kase K, Takeda Y, Terada N, Koba H, Tambo Y, Ohkura N, Abo M, Yano S. Patients with idiopathic pulmonary fibrosis and refractory cough have traction bronchiectasis and distorted airway architecture: a retrospective case review study. **J Thorac Dis.** 2024 Mar 29;16(3):2159-2166. doi: 10.21037/jtd-23-1443. Epub 2024 Mar 11.
 9. Iwasaki K, Okino R, Okazaki A, Kawashiri MA. Streptococcal Toxic Shock Syndrome caused by Streptococcus dysgalactiae subsp. equisimilis-related Empyema: A Novel Case Report. **Intern Med.** 2024 Apr 1;63(7):1021-1025. doi: 10.2169/ internal medicine. 2254-23. Epub 2023 Aug 9.
 10. Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells. **Cancer Lett.** 2024 Apr 10;587:216692. doi: 10.1016/ j. canlet.2024.216692. Epub 2024 Feb 9.
 11. Sakaguchi H, Nanjo S, Sato S, Kotani H, Nishiyama A, Yamashita K, Ohtsubo K, Suzuki C, Shimojima M, Yano S, Takeuchi S. Effectiveness of additional immunosuppressive drugs for corticosteroid-refractory immune checkpoint inhibitor-induced myocarditis: two case reports. **Intern Med.** 2025 Apr 15;64(8):1205-1210. doi: 10.2169/internal medicine.4162-24. Epub 2024 Sep 4.
 12. Abo M, Imamura K, Hosogi S, Kobayashi T, Takeda Y, Kase K, Koba H, Watanabe S, Ohkura N, Hara J, Yano S. Comparing region of interest selection and whole field analysis for measuring ciliary beat frequency in high-speed video analysis. **Respir Investig.** 2024 May;62(3): 419-425.doi: 10.1016/ j. resinv.2024.02.016. Epub 2024 Mar 14.
 13. Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L,

- Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. **Nat Commun.** 2024 May 3;15(1): 3741.doi: 10.1038/s41467-024-47423-0.
14. Azad TD, Nanjo S, Jin MC, Chabon JJ, Kurtz DM, Chaudhuri AA, Connolly ID, Hui AB, Liu CL, Merriott D, Ko R, Yoo C, Carter J, Chen E, Bonilla R, Hata A, Katakami N, Irie K, Yano S, Okimoto R, Bivona TG, Newman AM, Iv M, Nagpal S, Gephart MH, Alizadeh AA, Diehn M. Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. **NPJ Precis Oncol.** 2024 May 28;8(1): 121.doi: 10.1038/s41698-024-00582-1.
 15. Ishiura Y, Fujimura M, Ogawa H, Hara J, Shintani H, Hozawa S, Atsuta R, Fukumitsu K, Inoue H, Shioya T, Muraki M, Amemiya T, Ohkura N, Oribe Y, Tanaka H, Yamada T, Toyoshima M, Fujimori K, Ishizuka T, Kagaya M, Suzuki T, Kita T, Nishi K, Ueda A, Miyata Y, Kitada J, Yamamura K, Abo M, Takeda N, Shirai T, Tajiri T, Yoshihara S, Akamatsu T, Sawaguchi H, Nagano T, Hanada S, Masuda S, Ohmichi M, Ito T, Sagara H, Matsumoto H, Niimi A; Japan Cough Society. Prevalence and causes of chronic cough in Japan. **Respir Investig.** 2024 May;62(3): 442-448.doi: 10.1016 /j.resinv. 2024.02.017. Epub 2024 Mar 23.
 16. Fukuda K, Takeuchi S, Arai S, Nanjo S, Sato S, Kotani H, Kita K, Nishiyama A, Sakaguchi H, Ohtsubo K, Yano S. Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. **Cell Rep Med.** 2024 Jun 18;5(6): 101578.doi: 10.1016/j.xcrm.2024.101578. Epub 2024 May 21.
 17. Iwasaki K, Watanabe S, Kase K, Ohkura N, Saeki K, Tambo Y, Hara J, Abo M, Kimura H, Yano S. Prognostic value of coexisting conditions and complications in pleuroparenchymal fibroelastosis: a single-center retrospective study. **Sarcoidosis Vasc Diffuse Lung Dis.** 2024 Jun 28; 41(2): e2024014.doi: 10.36141/svdld. v41i2.13845.
 18. Okuma Y, Nomura S, Sakakibara-Konishi J, Tsukita Y, Murakami S, Hosomi Y, Tambo Y, Kogure Y, Yoshioka H, Tamiya M, Ninomiya K, Iwama E. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/ Paclitaxel/ Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas. **Clin Lung Cancer.** 2024 Jun;25(4): 389-394.doi: 10.1016/ j. clc. 2024.02.002. Epub 2024 Feb 8.
 19. Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo K, Nanjo S, Yano S, Mizuguchi K, Ikeda H, Takeuchi S. Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib. **Front Oncol.** 2024 Jul 8;

20. Kotani H, Oshima H, Boucher JC, Yamano T, Sakaguchi H, Sato S, Fukuda K, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Nishiuchi T, Oshima M, Davila ML, **Yano S**. Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage. **J Biomed Sci**. 2024 Jul 11;31(1):68. doi: 10.1186/s12929-024-01060-3.
21. Ohnishi H, Otani T, Kanemitsu Y, Nagano T, **Hara J**, Eitoku M. A systematic review and meta-analysis of macrolides in the management of adult patients with asthma. **Allergol Int**. 2024 Jul;73(3):382-389. doi: 10.1016/j.alit.2024.01.002.
22. Asano Y, Hayashi K, Takeuchi A, Kato S, Miwa S, Taniguchi Y, Okuda M, Matsumoto I, **Yano S**, Demura S. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases. **Int Immunopharmacol**. 2024 Jul 30;136:112276. doi: 10.1016/j.intimp.2024.112276. Epub 2024 May 30.
23. Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, **Yano S**, Takayama K. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. **Cancer Lett**. 2024 Aug 28: 598:217124.doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24.
24. Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, **Yano S**, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study. **Int J Clin Oncol**. 2024 Aug;29(8): 1142-1151.doi: 10.1007/s10147-024-02543-x. Epub 2024 May 17.
25. Sato Y, Sato Y, Irie K, **Nanjo S**, Hara S, Fujiwara S, Tomii K. Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib. **Thorac Cancer**. 2024 Aug; 15(23):1772-1775. doi: 10.1111/1759-7714.15395. Epub 2024 Jun 24.
26. Kotani H, Yamano T, Boucher JC, Sato S, Sakaguchi H, Fukuda K, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Nishiuchi T, Oshima H, Oshima M, Davila ML, **Yano S**. Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers. **Exp Hematol Oncol**. 2024 Sep 27;13(1):94. doi: 10.1186/s40164-024-00563-x.
27. Nakasuka F, Hirayama A, Makinoshima H, **Yano S**, Soga T, Tabata S. The role of cytidine 5'-

- triphosphate synthetase 1 in metabolic rewiring during epithelial-to-mesenchymal transition in non-small-cell lung cancer. **FEBS Open Bio.** 2024 Sep;14(9):1570-1583. doi: 10.1002/2211-5463.13860. Epub 2024 Jul 19.
28. **Tanaka S, Matsubayashi R, Tamori S**, Saito K, Nomura S. Rapidly worsening lung adenocarcinoma due to diffusely spreading lymphangitic carcinomatosis: A case report. **Clin Case Rep.** 2024 Oct 21; 12(10): e9494. doi: 10.1002/ccr3.9494. eCollection 2024 Oct.
 29. **Mizubishi K**. Myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis with silicosis, alveolar hemorrhage, and rapidly progressive glomerulonephritis: a case report. **AME Case Rep.** 2024 Oct 24;9:8. doi: 10.21037/acr-24-112. eCollection 2025.
 30. Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Kato S, Miwa S, Okuda M, Matsumoto I, **Yano S**, Demura S. Serum inflammatory dynamics as novel biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer with bone metastases. **Anticancer Res.** 2024 Oct;44(10): 4493-4503.doi: 10.21873/anticancer.17278.
 31. Nomura N, Matsumoto H, Asano K, Hayashi Y, Yokoyama A, Nishimura Y, Hashimoto N, Sakagami T, Fukunaga K, Hizawa N, Yamasaki A, Nagase H, Hattori N, Kondo M, Harada N, Sugiura H, Miki M, Kimura T, Toyoshima M, Matsuno O, Koh H, **Kita T**, Tomioka H, Tomii K, Ohnishi H, Takata S, Tobino K, Imokawa S, Sunadome H, Nagasaki T, Oguma T, Tanabe N, Hira T; BEXAS study. Refractory phenotype of Aspergillus-sensitized asthma with bronchiectasis and allergic bronchopulmonary aspergillosis. **J Allergy Clin Immunol Glob.** 2024 Nov 1;4(1):100364. doi: 10. 1016/ j.jacig. 2024.100364. eCollection 2025 Feb.
 32. **Iwasaki K, Watanabe S**, Ikku Y, **Yano S**. Successful osimertinib treatment for Meckel's cave metastasis: a case report. **Int Cancer Conf J.** 2024 Nov 8;14(1):56-59. doi: 10.1007/s13691-024-00736-9. eCollection 2025 Jan.
 33. Yamamoto S, Horita N, **Hara J**, Sasamoto M, Kanemitsu Y, Hara Y, Obase Y, Kaneko T, Niimi A, Mukae H. Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough: Dose-Response Model-Based Network Meta-Analysis. **Chest.** 2024 Nov;166(5): 1124-1140.doi: 10.1016 j.chest. 024.05.015. Epub 2024 Jun 8.
 34. **Tsukida S, Hongo M, Akasaki K, Sone T, Nishi K**. COVID-19 Pneumonia Diagnosed by Bronchoalveolar Lavage Fluid, With CD4 T-cell Depletion Contributing to Prolonged Infection: Two Case Reports. **Cureus.** 2024 Nov 25;16(11): e74380. doi: 10.7759/cureus.74380. eCollection 2024 Nov.
 35. **Terada N, Koba H, Nanjo S, Kimura H**, Nishiyama A, **Yoneda T, Takeda T, Shirasaki H, Nishi K**,

- Sone T**, Yamada T, Takayama K, Shibata K, Matsuoka H, Kita T, Nagata K, **Tambo Y**, **Ohkura N**, **Hara J**, **Kasahara K**, Kohsaka S, Mano H, **Yano S**. EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer. **Transl Lung Cancer Res.** 2024 Nov 28;13(11):3067–3082. doi: 10.21037/tlcr-24-471. Epub 2024 Nov 28.
36. **Hara R**, **Watanabe S**, **Terada N**, **Kase K**, **Muto A**, Hamaguchi Y, Matsushita T, Ikeda H, Tanaka T, **Yano S**. The lung as a site for the generation of anti-MDA5 antibody in clinically amyopathic dermatomyositis. **Rheumatology (Oxford).** 2024 Dec 1;63(12): e336-e338.doi: 10.1093/rheumatology/keae314.
37. Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, **Tambo Y**, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01. **Eur J Cancer.** 2024 Dec: 213:115117. doi: 10.1016/j.ejca.2024.115117.
38. Ohtsubo K, Miyake K, Sato S, Sakaguchi H, Fukuda K, Kotani H, Nishiyama A, **Nanjo S**, Yamashita K, Takeuchi S, **Yano S**, Kuruma S, Nakahodo J, Kikuyama M, Taniguchi H. Analysis of methylation of tumor-suppressive miRNA and KRAS/TP53 mutations in pancreatic juice. **Anticancer Res.** 2024 Dec;44(12): 5253-5261.doi: 10.21873/anticanres.17353.